ClinicalTrials.gg
CompletedNCT03785405Updated May 16, 2025Results posted

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

A Phase 3 interventional study of sacubitril/valsartan in Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 79 sites in 27 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing sacubitril in Heart Failure — 5 open to participants now, 5 under way, 2 of them phase 3. sacubitril · Heart Failure.

Enrollment
9th of 24
216 · median 104
Started
2019
with 3 others
Phase 3
7 of 24
2 open now
Registered
9th of 24
by date
Lead sponsor
5 of 24
Novartis Pharmaceuticals

Among the 24 studies testing sacubitril in Heart Failure, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 7 in phase 3, and was the 9th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 24 studies testing sacubitril in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sacubitril

sacubitril: first FDA approval 2015 (ENTRESTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing sacubitril in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2 as per protocol.

Read the detailed description

This was a multicenter, open-label long-term extension study for participants who successfully completed PANORAMA-HF core study Part 2 of the trial or who discontinued study drug treatment early in Part 2 due to the implementation of Urgent safety measure (USM) of PANORAMA-HF core study. Provided that they fulfilled the protocol requirements, these patients were eligible to participate in the OLE. Depending on when and where the participant was enrolled, the duration of the study was of a minimum of 1 year, or until receipt of local marketing authorization and commercial availability, or reaching the maximum limit allowed by local regulations, or until Dec-2023, whichever occurred first.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • heart failure
  • pediatric
  • LCZ696
  • sacubitril/valsartan
  • open-label study
  • angiotensin receptor neprilysin inhibitor
  • PANORAMA-HF
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • On study drug at PANORAMA-HF Part 2 EOS visit. Does not have any significant safety issue

Exclusion criteria

Exclusion Criteria:

  • Subject only participated in PANORAMA-HF Part 1 or was a SF in PANORAMA-HF or permanently discontinued study drug in PANORMA-HF Part 2
  • Use of drugs within 5 half-lives of enrollment or within 30 days (longer duration); with the exception of PANORAMA-HF study drug (requires >/=36-hour before baseline visit)
  • History of or allergy to study treatment, its or drugs of similar chemical class, ACEIs, ARBs, or NEP inhibitor and known/suspected to sacubitril/valsartan
  • Renal vascular hypertension (including renal artery stenosis)
  • Significant renal estimated disorder (eGFR calculated using modified Schwartz formula \<30% mean GFR for age); hepatic disorder (serum or alanine aminotransferase > 3 times ); gastrointestinal disorder or biliary disorder
  • History of angioedema
  • Parents or legal guardians of subject who do not give consent or allow the child to give assent, or inability of patient or parents/legal guardians to follow instructions or comply with follow-up procedures
  • Any medical condition(s) that may put the patient at risk in the investigator's opinion or that the investigator deems unsuitable for the study
  • Other protocol defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    sacubitril/valsartan

    single arm, open label sacubitril/valsartan

    Drug: sacubitril/valsartan

Interventions

  • Drugsacubitril/valsartan

    Drug pages: Sacubitril · Valsartan

    Target dose 3.1 mg/kg bid Formulations: Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)

    Also known as: LCZ696

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Number of participants with at least one Adverse Events (AEs)

    Time frame: to end of study, up to 4,5 years

  2. Number of Participants With Serious Adverse Events

    Number of participants with at least one Serious Adverse Events (SAEs)

    Time frame: to end of study, up to 4.5 years

  3. Duration of Drug Exposure

    Median duration of exposure to sacubitril/valsartan (including temporary interruptions)

    Time frame: Up to 4.5 years

07

Results

Posted Jul 16, 2024

Participant flow

79 centers in 27 countries: Korea, Republic of(4), United States(15), Bulgaria(1), Italy(7), Thailand(2), Poland(2), Japan(8), Singapore(2), Israel(1), Turkey(3), Taiwan(2), South Africa(1), Portugal(3), Lebanon(2), Canada(2), Switzerland(1), Czech Republic(1), Croatia(1), Argentina(1), Hungary(1), India(4), Germany(5), France(1), Austria(1), Spain(5), Russia(2), Finland(1)

Participant flow — Overall Study
MilestoneAge Group 1Age Group 2
Started13086
Safety set (saf)13085
Completed9274
Not completed3812
Withdrew: Adverse event161
Withdrew: Death64
Withdrew: Guardian decision41
Withdrew: Lost to follow-up10
Withdrew: Physician decision85
Withdrew: Participant decision20
Withdrew: Other10
Withdrew: No treatment was received01

Outcome measures

PrimaryNumber of Participants With Adverse Events

Number of participants with at least one Adverse Events (AEs)

Time frame:
to end of study, up to 4,5 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsAge Group 1Age Group 2
Number of Participants With Adverse Events11178
PrimaryNumber of Participants With Serious Adverse Events

Number of participants with at least one Serious Adverse Events (SAEs)

Time frame:
to end of study, up to 4.5 years
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsAge Group 1Age Group 2
Number of Participants With Serious Adverse Events5925
PrimaryDuration of Drug Exposure

Median duration of exposure to sacubitril/valsartan (including temporary interruptions)

Time frame:
Up to 4.5 years
Reported as:
Median · Days
Duration of Drug Exposure
DaysAge Group 1Age Group 2
Duration of Drug Exposure894 (23 to 1612)951 (62 to 1570)

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Age Group 17/130 (5.4%)59/130 (45.4%)90/130 (69.2%)
Age Group 24/85 (4.7%)25/85 (29.4%)60/85 (70.6%)
Total11/215 (5.1%)84/215 (39.1%)150/215 (69.8%)
Most frequent serious events
Showing 10 of 111
Most frequent serious events
EventAge Group 1Age Group 2Total
Cardiac failureCardiac disorders15/1303/8518/215
COVID-19Infections and infestations4/1304/858/215
PneumoniaInfections and infestations5/1304/859/215
Dilated cardiomyopathyCardiac disorders5/1300/855/215
Chest painGeneral disorders5/1300/855/215
PyrexiaGeneral disorders3/1303/856/215
Cardiac failure chronicCardiac disorders4/1302/856/215
GastroenteritisInfections and infestations4/1302/856/215
Cardiac failure acuteCardiac disorders2/1302/854/215
VomitingGastrointestinal disorders3/1302/855/215
Most frequent other events
Showing 10 of 22
Most frequent other events
EventAge Group 1Age Group 2Total
COVID-19Infections and infestations23/13024/8547/215
PyrexiaGeneral disorders15/13022/8537/215
Upper respiratory tract infectionInfections and infestations8/13022/8530/215
CoughRespiratory, thoracic and mediastinal disorders20/13019/8539/215
NasopharyngitisInfections and infestations12/13014/8526/215
VomitingGastrointestinal disorders15/13012/8527/215
HypotensionVascular disorders18/1303/8521/215
HeadacheNervous system disorders15/1303/8518/215
DizzinessNervous system disorders14/1300/8514/215
DiarrhoeaGastrointestinal disorders9/1309/8518/215

Baseline characteristics

Baseline Participants are based on the Safety Set (SAF) population, as primary analysis are based on the SAF.

Age, Continuous
Age, Continuous(Years)Age Group 1Age Group 2Total
Mean12.83 ± 3.8642.94 ± 1.1498.92 ± 5.747
Sex: Female, Male
Sex: Female, Male(Participants)Age Group 1Age Group 2Total
Female6049109
Male7036106
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Age Group 1Age Group 2Total
American Indian or Alaska Native202
White7841119
Asian242347
Black or African American191029
Multiple044
Native Hawaiian or Other Pacific Islander011
Unknown7613
08

Study locations

79 sites
  • Novartis Investigative Site
    Loma Linda, California 92354, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    Palo Alto, California 94304, United States
  • Novartis Investigative Site
    Saint Petersburg, Florida 33701, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30322, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46202, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109-5238, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63110, United States
  • Novartis Investigative Site
    New York, New York 10032, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28203, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15224, United States
  • Novartis Investigative Site
    Ciudad de Salta, Provincia De Salta A4406BPF, Argentina
  • Novartis Investigative Site
    Innsbruck, 6020, Austria
  • Novartis Investigative Site
    Sofia, 1309, Bulgaria
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1C9, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 1X8, Canada
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Praha 5, 150 06, Czechia
  • Novartis Investigative Site
    Helsinki, 00290, Finland
  • Novartis Investigative Site
    Paris 15, 75015, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Stuttgart, 70174, Germany
  • Novartis Investigative Site
    Budapest, H 1096, Hungary
  • Novartis Investigative Site
    New Delhi, Delhi 110076, India
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380 060, India
  • Novartis Investigative Site
    Kochi, Kerala 682041, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Beer Sheva, 84101, Israel
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Firenze, FI 50132, Italy
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Roma, RM 00165, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Obu, Aichi 474 8710, Japan
  • Novartis Investigative Site
    Sapporo city, Hokkaido 060 8648, Japan
  • Novartis Investigative Site
    Omura, Nagasaki 856-8562, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113 8655, Japan
  • Novartis Investigative Site
    Setagaya-ku, Tokyo 157-8535, Japan
  • Novartis Investigative Site
    Shinjuku ku, Tokyo 162 8666, Japan
  • Novartis Investigative Site
    Toyama-city, Toyama 930-0194, Japan
  • Novartis Investigative Site
    Saitama, 330 8777, Japan
  • Novartis Investigative Site
    Yangsan Si, Gyeongsangnam Do 50612, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Ashrafieh, 166830, Lebanon
  • Novartis Investigative Site
    Beirut, 10999, Lebanon
  • Novartis Investigative Site
    Warszawa, 04 730, Poland
  • Novartis Investigative Site
    Wroclaw, 51-124, Poland
  • Novartis Investigative Site
    Carnaxide, Lisboa 2799 523, Portugal
  • Novartis Investigative Site
    Coimbra, 3000 075, Portugal
  • Novartis Investigative Site
    Lisboa, 1169 024, Portugal
  • Novartis Investigative Site
    Moscow, 125412, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197341, Russian Federation
  • Novartis Investigative Site
    Singapore, 119260, Singapore
  • Novartis Investigative Site
    Singapore, 229899, Singapore
  • Novartis Investigative Site
    Soweto, Gauteng 2013, South Africa
  • Novartis Investigative Site
    Cordoba, Andalucia 14004, Spain
  • Novartis Investigative Site
    Esplugues De Llobregat, Barcelona 08950, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Tainan, 70403, Taiwan
  • Novartis Investigative Site
    Taipei, 10041, Taiwan
  • Novartis Investigative Site
    Bangkoknoi, Bangkok 10700, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Ankara, 06490, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Konak-Izmir, 35210, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Dec 2023, 55 months.

Results were first posted in Jul 2024, 6 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 55 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2018
First posted
Dec 24, 2018
StartActual
May 2, 2019
Primary completionActual
Dec 29, 2023
CompletionActual
Dec 29, 2023
Results first posted
Jul 16, 2024
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03785405
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
May 2, 2019
Primary completion
Dec 29, 2023
Completion
Dec 29, 2023
Results posted
Jul 16, 2024
Last update
May 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacubitril · Valsartan

Start the discussion